BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33889297)

  • 1. Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra
    White T; Szelinger S; LoBello J; King A; Aldrich J; Garinger N; Halbert M; Richholt RF; Mastrian SD; Babb C; Ozols AA; Goodman LJ; Basu GD; Royce T
    Oncotarget; 2021 Apr; 12(8):726-739. PubMed ID: 33889297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay.
    Saldivar JS; Harris J; Ayash E; Hong M; Tandon P; Sinha S; Hebron PM; Houghton EE; Thorne K; Goodman LJ; Li C; Marfatia TR; Anderson J; Morra M; Lyle J; Bartha G; Chen R
    Oncotarget; 2023 Aug; 14():789-806. PubMed ID: 37646774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical validation and clinical utilization of K-4CARE™: a comprehensive genomic profiling assay with personalized MRD detection.
    Nguyen Hoang TP; Nguyen TA; Tran NHB; Nguyen Hoang VA; Thi Dao HT; Tran VU; Nguyen YN; Nguyen AT; Nguyen Thi CT; Do Thi TT; Nguyen DS; Nguyen HN; Giang H; Tu LN
    Front Mol Biosci; 2024; 11():1334808. PubMed ID: 38404964
    [No Abstract]   [Full Text] [Related]  

  • 6. An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing.
    Malhotra R; Javle V; Tanwar N; Gowda P; Varghese L; K A; Madhusudhan N; Jaiswal N; K S B; Chatterjee M; Prabhash K; Sreekanthreddy P; Rishi KD; Goswami HM; Veldore VH
    Front Oncol; 2023; 13():1002792. PubMed ID: 36994199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
    Beg S; Bareja R; Ohara K; Eng KW; Wilkes DC; Pisapia DJ; Zoughbi WA; Kudman S; Zhang W; Rao R; Manohar J; Kane T; Sigouros M; Xiang JZ; Khani F; Robinson BD; Faltas BM; Sternberg CN; Sboner A; Beltran H; Elemento O; Mosquera JM
    Transl Oncol; 2021 Jan; 14(1):100944. PubMed ID: 33190043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive next generation sequencing tissue assay for Asian-prevalent cancers-Analytical validation and performance evaluation with clinical samples.
    Ng CC; Lim S; Lim AH; Md Nasir ND; Zhang J; Rajasegaran V; Lee JY; Kok JST; Thike AA; Lim JX; Weng R; Yee S; Choudhury Y; Chan JY; Tan PH; Tan MH; Teh BT
    Front Mol Biosci; 2022; 9():963243. PubMed ID: 36213130
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors.
    Froyen G; Geerdens E; Berden S; Cruys B; Maes B
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection.
    Atkins A; Gupta P; Zhang BM; Tsai WS; Lucas J; Javey M; Vora A; Mei R
    Mol Diagn Ther; 2019 Aug; 23(4):521-535. PubMed ID: 31209714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test.
    Tomlins SA; Hovelson DH; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
    J Mol Diagn; 2021 Nov; 23(11):1515-1533. PubMed ID: 34454112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
    Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
    ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series.
    Drenner K; Basu GD; Goodman LJ; Ozols AA; LoBello JR; Royce T; Gordon MS; Borazanci EH; Steinbach MA; Trent J; Sharma S
    Oncotarget; 2021 Aug; 12(18):1836-1847. PubMed ID: 34504655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay.
    Beaubier N; Tell R; Lau D; Parsons JR; Bush S; Perera J; Sorrells S; Baker T; Chang A; Michuda J; Iguartua C; MacNeil S; Shah K; Ellis P; Yeatts K; Mahon B; Taxter T; Bontrager M; Khan A; Huether R; Lefkofsky E; White KP
    Oncotarget; 2019 Mar; 10(24):2384-2396. PubMed ID: 31040929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive NGS Panel Validation for the Identification of Actionable Alterations in Adult Solid Tumors.
    Martínez-Fernández P; Pose P; Dolz-Gaitón R; García A; Trigo-Sánchez I; Rodríguez-Zarco E; Garcia-Ruiz M; Barba I; Izquierdo-García M; Valero-Garcia J; Ruiz C; Lázaro M; Carbonell P; Gargallo P; Méndez C; Ríos-Martín JJ; Palmeiro-Uriach A; Camarasa-Lillo N; Forteza-Vila J; Calabria I
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33947144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.